Get started

Dynavax

Dynavax Technologies dropping. DVAXFlat formation with C wave underway. Some fib levels are shown, as with most flats the expectation is the C wave will end more or less around A/B pivot. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:DVAXShort
by Rykin_Capital
Can Covid Vax Spark DVAX?DVAX retracement plotted using recent lows and the high from Aug 2018...figured that would be more than enough on the big picture to see any potential levels of interest. In this case, sure enough, there were. Mainly, the 236 fib line has been an area of higher traffic over the last 3 years. Further, DVAX has yet to establish a substantial support above this level for an extended period of time. Thanks to the Delta variant, COVID vax is in focus. For DVAX however, there are possibly a few other things to keep in mind that could be important to keep in mind right now: " Conveniently for those just beginning to look at DVAX stock right now, the company gave an overview of its platforms earlier this month in a second-quarter earnings update. Its HEPLISAV-B and CpG 1018 platforms generated revenue for the quarter, with $39 million coming from CpG 1018 and $13.7 million from HEPLISAV-B. In particular, the HEPLISAV-B revenues were the highest quarterly figures for the treatment to date. Dynavax has gone further and entered into a commercialization agreement with Bavarian Nordic for the German market...With the coronavirus continuing to stoke uncertainty, vaccine stocks remain in focus. Dynavax’s CpG 1018 adjuvant has acted as a recent catalyst. The adjuvant is designed to increase vaccine immune response when used in vaccines, including its own HEPLISAV-B. Now, with coronavirus vaccines showing benefits, the uptick in cases has helped build more interest in the company’s pipeline...In fact, Dynavax has entered into commercial supply agreements with numerous companies, including Biological E and Clover Biopharmaceuticals, to use Dynavax’s adjuvant in the commercial production of each company’s respective coronavirus vaccine candidates. " Quote Source + Read more: Hot Biotech Stocks That Deserve Your Attention In August 2021
NASDAQ:DVAX
by PennyStocks101
DVAX- Is Approaching A Critical Level: 50%/120% potential profitDVAX - Is Approaching A Critical Level: DVAX- Is Approaching A Critical Level: 50%/120% potential profit Here’s A Way to Play It. see chart info: DVAX Dynavax Technologies Corporation Healthcare | Biotechnology | USA NEWS for Dynavax Technologies Corporation : as of August 13, 2020 www.fool.com finance.yahoo.com DISCLAIMER: Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks and options may fluctuate, and, as a result, may lose more than their original investment. All trading strategies , CHART are used at your own risk. ...
NASDAQ:DVAXLong
by Voxeurh514
2019 Looks Bright, SD-101 should send stocks soaringDynavax recently presented a company outlook for 2019 at the JP Morgan Healthcare Conference. During the presentation, CEO Eddie Gray revealed encouraging HEPISLAV-B sales for Q4 of ~$3.7M. 2018 was a big year for Dynavax's lead immuno-oncology candidate SD-101. The company has stated they are looking for a potential partner for their planned Phase III in melanoma. The stock experienced a strong sell-off in Q4, but the new year should treat DVAX well. In its March 2019 Cowen presentation, Dynavax issued a pipeline slide. Although I note a lack of phase 3 candidates. It has but a single therapy, SD-101, in phase 2 that it is advancing in combination with Merck's Keytruda (pembrolizumab) in various combinations. Positive news from SD-101 should send stocks soaring.
NASDAQ:DVAXLong
by warrenhochfeld
DVAX - Aggressive Swing TradeThis is an aggressive swing trade that I will be placing early Monday unless the markets look extremely bearish. I am calling this an aggressive trade because of the obvious roadblocks that it will need to overcome in order to reach the target. Also because If I am triggered into the trade and it moves in my favor I will be quickly moving my stop loss up to mitigate my risk as soon as possible just in case one of the roadblocks does, in fact, prove to be insurmountable. Here are the things I like about this trade 1) The price is bouncing off of the 200 SMA 2) The last 3 candles have formed a morning star reversal pattern Here are the potential roadblocks facing this trade 1) The price must break through a fairly strong looking resistance in order to reach the target. 2) The 100 SMA is dropping and will most likely pose a strong resistance as it has in the past. Here is my set up 1) My Bullish stop limit - place the buy stop at $16.75 and the limit at $16.78 2) My stop loss will be placed at $15.55 and my 2R profit target will be at $19.15
NASDAQ:DVAXLong
by Bigsky_Crypto
1